<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339854</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1378</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091378</ELocationID><Abstract><AbstractText>Hepatitis E virus (HEV) poses a significant global health threat, with an estimated 20 million infections occurring annually. Despite being a self-limiting illness, in most cases, HEV infection can lead to severe outcomes, particularly in pregnant women and individuals with pre-existing liver disease. In the absence of specific antiviral treatments, the exploration of RNAi interference (RNAi) as a targeted strategy provides valuable insights for urgently needed therapeutic interventions against Hepatitis E. We designed small interfering RNAs (siRNAs) against HEV, which target the helicase domain and the open reading frame 3 (ORF3). These target regions will reduce the risk of viral escape through mutations, as they belong to the most conserved regions in the HEV genome. The siRNAs targeting the ORF3 efficiently inhibited viral replication in A549 cells after HEV infection. Importantly, the siRNA was also highly effective at inhibiting HEV in the persistently infected A549 cell line, which provides a suitable model for chronic infection in patients. Furthermore, we showed that a 5' triphosphate modification on the siRNA sense strand activates the RIG-I receptor, a cytoplasmic pattern recognition receptor that recognizes viral RNA. Upon activation, RIG-I triggers a signaling cascade, effectively suppressing HEV replication. This dual-action strategy, combining the activation of the adaptive immune response and the inherent RNAi pathway, inhibits HEV replication successfully and may lead to the development of new therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ziersch</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0729-7321</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Viral Gastroenteritis and Hepatitis Pathogens and Enterovirus, Robert Koch Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumair</LastName><ForeName>Lena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0008-5904-0791</Identifier><AffiliationInfo><Affiliation>Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurreck</LastName><ForeName>Anke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BioNukleo GmbH, Ackerstrasse 76, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johne</LastName><ForeName>Reimar</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9597-6724</Identifier><AffiliationInfo><Affiliation>Department of Biological Safety, German Federal Institute for Risk Assessment, 12277 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bock</LastName><ForeName>C-Thomas</ForeName><Initials>CT</Initials><Identifier Source="ORCID">0000-0002-2773-486X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Division of Viral Gastroenteritis and Hepatitis Pathogens and Enterovirus, Robert Koch Institute, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurreck</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1469-0052</Identifier><AffiliationInfo><Affiliation>Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>16KN073265</GrantID><Agency>Federal Ministry for Economic Affairs and Climate Action</Agency><Country /></Grant><Grant><GrantID>16KN073266</GrantID><Agency>Federal Ministry for Economic Affairs and Climate Action</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C452820">RIGI protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C400973">ORF3 protein, Hepatitis E virus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016752" MajorTopicYN="Y">Hepatitis E virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="Y">DEAD Box Protein 58</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="Y">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="Y">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016751" MajorTopicYN="N">Hepatitis E</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HEV</Keyword><Keyword MajorTopicYN="N">RIG-I</Keyword><Keyword MajorTopicYN="N">RNA 5′triphosphate</Keyword><Keyword MajorTopicYN="N">RNAi therapy</Keyword><Keyword MajorTopicYN="N">siRNA</Keyword></KeywordList><CoiStatement>Author Anke Kurreck was employed by the BioNukleo GmbH. The other authors declare no conflicts of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339854</ArticleId><ArticleId IdType="pmc">PMC11435946</ArticleId><ArticleId IdType="doi">10.3390/v16091378</ArticleId><ArticleId IdType="pii">v16091378</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO-Hepatitis, E.  [(accessed on 9 July 2024)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/hepatitis-e.</Citation></Reference><Reference><Citation>Nelson K.E., Labrique A.B., Kmush B.L. Epidemiology of Genotype 1 and 2 Hepatitis E Virus Infections. Cold Spring Harb. Perspect. Med. 2019;9:a031732. doi: 10.1101/cshperspect.a031732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a031732</ArticleId><ArticleId IdType="pmc">PMC6546036</ArticleId><ArticleId IdType="pubmed">29735579</ArticleId></ArticleIdList></Reference><Reference><Citation>Doceul V., Bagdassarian E., Demange A., Pavio N. Zoonotic Hepatitis E Virus: Classification, Animal Reservoirs and Transmission Routes. Viruses. 2016;8:270. doi: 10.3390/v8100270.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8100270</ArticleId><ArticleId IdType="pmc">PMC5086606</ArticleId><ArticleId IdType="pubmed">27706110</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Poel W.H. Food and Environmental Routes of Hepatitis e Virus Transmission. Curr. Opin. Virol. 2014;4:91–96. doi: 10.1016/j.coviro.2014.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2014.01.006</ArticleId><ArticleId IdType="pubmed">24513966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Liu J., Li Y., Su J., Ma Z., Bramer W.M., Cao W., de Man R.A., Peppelenbosch M.P., Pan Q. The Global Epidemiology of Hepatitis E Virus Infection: A Systematic Review and Meta-analysis. Liver Int. 2020;40:1516–1528. doi: 10.1111/liv.14468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14468</ArticleId><ArticleId IdType="pmc">PMC7384095</ArticleId><ArticleId IdType="pubmed">32281721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lhomme S., Marion O., Abravanel F., Izopet J., Kamar N. Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. J. Clin. Med. 2020;9:331. doi: 10.3390/jcm9020331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020331</ArticleId><ArticleId IdType="pmc">PMC7073673</ArticleId><ArticleId IdType="pubmed">31991629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Selves J., Mansuy J.-M., Ouezzani L., Péron J.-M., Guitard J., Cointault O., Esposito L., Abravanel F., Danjoux M., et al. Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. N. Engl. J. Med. 2008;358:811–817. doi: 10.1056/NEJMoa0706992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0706992</ArticleId><ArticleId IdType="pubmed">18287603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton H.R., Bendall R.P., Keane F.E., Tedder R.S., Ijaz S. Persistent Carriage of Hepatitis E Virus in Patients with HIV Infection. N. Engl. J. Med. 2009;361:1025–1027. doi: 10.1056/NEJMc0903778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc0903778</ArticleId><ArticleId IdType="pubmed">19726781</ArticleId></ArticleIdList></Reference><Reference><Citation>Haboubi H.N.Y., Diyar R., Benton A., Ch’ng C.L. A Case of Acute Hepatitis E Infection in a Patient with Non-Hodgkin Lymphoma Treated Successfully with Ribavirin. Case Rep. Gastrointest. Med. 2017;2017:8941218. doi: 10.1155/2017/8941218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8941218</ArticleId><ArticleId IdType="pmc">PMC5274689</ArticleId><ArticleId IdType="pubmed">28182129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Rostaing L., Legrand-Abravanel F., Izopet J. How Should Hepatitis E Virus Infection Be Defined in Organ-Transplant Recipients? Am. J. Transplant. 2013;13:1935–1936. doi: 10.1111/ajt.12253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.12253</ArticleId><ArticleId IdType="pubmed">23659713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Izopet J., Dalton H.R. Chronic Hepatitis E Virus Infection and Treatment. J. Clin. Exp. Hepatol. 2013;3:134–140. doi: 10.1016/j.jceh.2013.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jceh.2013.05.003</ArticleId><ArticleId IdType="pmc">PMC3940092</ArticleId><ArticleId IdType="pubmed">25755487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry S.A., Verma N., Koren G. Hepatitis E Infection during Pregnancy. Can. Fam. Physician. 2015;61:607–608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501603</ArticleId><ArticleId IdType="pubmed">26175368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenney S.P., Meng X.J. Hepatitis E Virus Genome Structure and Replication Strategy. Cold Spring Harb. Perspect. Med. 2019;9:a031724. doi: 10.1101/cshperspect.a031724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a031724</ArticleId><ArticleId IdType="pmc">PMC6314074</ArticleId><ArticleId IdType="pubmed">29530948</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson R.A., Burgess W.H., Emerson S.U., Leibowitz R.S., Sosnovtseva S.A., Tsarev S., Purcell R.H. Structural Characterization of Recombinant Hepatitis E Virus ORF2 Proteins in Baculovirus-Infected Insect Cells. Protein Expr. Purif. 1998;12:75–84. doi: 10.1006/prep.1997.0817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/prep.1997.0817</ArticleId><ArticleId IdType="pubmed">9473460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K., Takahashi M., Hoshino Y., Takahashi H., Ichiyama K., Nagashima S., Tanaka T., Okamato H. ORF3 Protein of Hepatitis E Virus Is Essential for Virion Release from Infected Cells. J. Gen. Virol. 2009;90:1880–1891. doi: 10.1099/vir.0.010561-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.010561-0</ArticleId><ArticleId IdType="pubmed">19339479</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafrullah M., Ozdener M.H., Panda S.K., Jameel S. The ORF3 Protein of Hepatitis E Virus Is a Phosphoprotein That Associates with the Cytoskeleton. J. Virol. 1997;71:9045–9053. doi: 10.1128/jvi.71.12.9045-9053.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.71.12.9045-9053.1997</ArticleId><ArticleId IdType="pmc">PMC230205</ArticleId><ArticleId IdType="pubmed">9371561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q., Heller B., Capuccino J.M.V., Song B., Nimgaonkar I., Hrebikova G., Contreras J.E., Ploss A. Hepatitis E Virus ORF3 Is a Functional Ion Channel Required for Release of Infectious Particles. Proc. Natl. Acad. Sci. USA. 2017;114:1147–1152. doi: 10.1073/pnas.1614955114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1614955114</ArticleId><ArticleId IdType="pmc">PMC5293053</ArticleId><ArticleId IdType="pubmed">28096411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sari G., Zhu J., Ambardekar C., Yin X., Boonstra A., Feng Z., Vanwolleghem T. The Viral ORF3 Protein Is Required for Hepatitis E Virus Apical Release and Efficient Growth in Polarized Hepatocytes and Humanized Mice. J. Virol. 2021;95:0058521. doi: 10.1128/JVI.00585-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00585-21</ArticleId><ArticleId IdType="pmc">PMC8577391</ArticleId><ArticleId IdType="pubmed">34523963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair V.P., Anang S., Subramani C., Madhvi A., Bakshi K., Srivastava A., Shalimar, Nayak B., Ranjith Kumar C.T., Surjit M. Endoplasmic Reticulum Stress Induced Synthesis of a Novel Viral Factor Mediates Efficient Replication of Genotype-1 Hepatitis E Virus. PLoS Pathog. 2016;12:1005521. doi: 10.1371/journal.ppat.1005521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005521</ArticleId><ArticleId IdType="pmc">PMC4817972</ArticleId><ArticleId IdType="pubmed">27035822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Abravanel F., Selves J., Garrouste C., Esposito L., Lavayssière L., Cointault O., Ribes D., Cardeau I., Nogier M.B., et al. Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection after Organ Transplantation. Transplantation. 2010;89:353–360. doi: 10.1097/TP.0b013e3181c4096c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3181c4096c</ArticleId><ArticleId IdType="pubmed">20145528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Rostaing L., Abravanel F., Garrouste C., Esposito L., Cardeau-Desangles I., Mansuy J.M., Selves J., Peron J.M., Otal P., et al. Pegylated Interferon-α for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation. Clin. Infect. Dis. 2010;50:e30–e33. doi: 10.1086/650488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/650488</ArticleId><ArticleId IdType="pubmed">20113176</ArticleId></ArticleIdList></Reference><Reference><Citation>Alric L., Bonnet D., Laurent G., Kamar N., Izopet J. Chronic Hepatitis E Virus Infection: Successful Virologic Response to Pegylated Interferon-Alpha Therapy. Ann. Intern. Med. 2010;153:135–136. doi: 10.7326/0003-4819-153-2-201007200-00256.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-2-201007200-00256</ArticleId><ArticleId IdType="pubmed">20547885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Izopet J., Tripon S., Bismuth M., Hillaire S., Dumortier J., Radenne S., Coilly A., Garrigue V., D’Alteroche L., et al. Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. N. Engl. J. Med. 2014;370:1111–1120. doi: 10.1056/NEJMoa1215246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215246</ArticleId><ArticleId IdType="pubmed">24645943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Rostaing L., Abravanel F., Garrouste C., Lhomme S., Esposito L., Basse G., Cointault O., Ribes D., Nogier M.B., et al. Ribavirin Therapy Inhibits Viral Replication on Patients with Chronic Hepatitis E Virus Infection. Gastroenterology. 2010;139:1612–1618. doi: 10.1053/j.gastro.2010.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.08.002</ArticleId><ArticleId IdType="pubmed">20708006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N., Abravanel F., Behrendt P., Hofmann J., Pageaux G.P., Barbet C., Moal V., Couzi L., Horvatits T., Man R.A., et al. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clin. Infect. Dis. 2020;71:1204–1211. doi: 10.1093/cid/ciz953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz953</ArticleId><ArticleId IdType="pubmed">31793638</ArticleId></ArticleIdList></Reference><Reference><Citation>Todt D., Gisa A., Radonic A., Nitsche A., Behrendt P., Suneetha P.V., Pischke S., Bremer B., Brown R.J.P., Manns M.P., et al. In Vivo Evidence for Ribavirin-Induced Mutagenesis of the Hepatitis E Virus Genome. Gut. 2016;65:1733–1743. doi: 10.1136/gutjnl-2015-311000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311000</ArticleId><ArticleId IdType="pmc">PMC5036239</ArticleId><ArticleId IdType="pubmed">27222534</ArticleId></ArticleIdList></Reference><Reference><Citation>Debing Y., Ramière C., Dallmeier K., Piorkowski G., Trabaud M.-A., Lebossé F., Scholtès C., Roche M., Legras-Lachuer C., Lamballerie X., et al. Hepatitis E Virus Mutations Associated with Ribavirin Treatment Failure Result in Altered Viral Fitness and Ribavirin Sensitivity. J. Hepatol. 2016;65:499–508. doi: 10.1016/j.jhep.2016.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2016.05.002</ArticleId><ArticleId IdType="pubmed">27174035</ArticleId></ArticleIdList></Reference><Reference><Citation>Debing Y., Gisa A., Dallmeier K., Pischke S., Bremer B., Manns M., Wedemeyer H., Suneetha P.V., Neyts J. A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates with Ribavirin Treatment Failure in Organ Transplant Recipients. Gastroenterology. 2014;147:1008–1011. doi: 10.1053/j.gastro.2014.08.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.08.040</ArticleId><ArticleId IdType="pubmed">25181691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorris M., van der Lecq B.M., van Erpecum K.J., de Bruijne J. Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis. J. Viral Hepat. 2021;28:454–463. doi: 10.1111/jvh.13456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13456</ArticleId><ArticleId IdType="pmc">PMC7898834</ArticleId><ArticleId IdType="pubmed">33301609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Zhong L., Weng Y., Peng L., Huang Y., Zhao Y., Liang X.-J. Therapeutic siRNA: State of the Art. Signal Transduct. Target. Ther. 2020;5:101. doi: 10.1038/s41392-020-0207-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0207-x</ArticleId><ArticleId IdType="pmc">PMC7305320</ArticleId><ArticleId IdType="pubmed">32561705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurreck J. RNA Interference: From Basic Research to Therapeutic Applications. Angew. Chem. Int. Ed Engl. 2009;48:1378–1398. doi: 10.1002/anie.200802092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200802092</ArticleId><ArticleId IdType="pmc">PMC7159607</ArticleId><ArticleId IdType="pubmed">19153977</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Hua X., Yang S., Yuan C., Zhang W. Effective Inhibition of Hepatitis E Virus Replication in A549 Cells and Piglets by RNA Interference (RNAi) Targeting RNA-Dependent RNA Polymerase. Antivir. Res. 2009;83:274–281. doi: 10.1016/j.antiviral.2009.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.06.008</ArticleId><ArticleId IdType="pmc">PMC7114333</ArticleId><ArticleId IdType="pubmed">19576249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Panda S.K., Durgapal H., Acharya S.K., Rehman S., Kar U.K. Inhibition of Hepatitis E Virus Replication Using Short Hairpin RNA (shRNA) Antivir. Res. 2010;85:541–550. doi: 10.1016/j.antiviral.2010.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.01.005</ArticleId><ArticleId IdType="pubmed">20105445</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Zhou J., Yang Z., Cui L., Zhang W., Yuan C., Yang S., Zhu J., Hua X. RNA Interference Inhibits Hepatitis E Virus mRNA Accumulation and Protein Synthesis in Vitro. Vet. Microbiol. 2010;142:261–267. doi: 10.1016/j.vetmic.2009.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2009.10.023</ArticleId><ArticleId IdType="pmc">PMC7117326</ArticleId><ArticleId IdType="pubmed">19963327</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Lei M., Jiao H., Du L., Cheng Y., Zhang D., Hao Y., Man C., Wang F. RNA Interference Induces Effective Inhibition of mRNA Accumulation and Protein Expression of SHEV ORF3 Gene in Vitro. Curr. Microbiol. 2011;62:1355–1362. doi: 10.1007/s00284-010-9863-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-010-9863-3</ArticleId><ArticleId IdType="pubmed">21225263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Freistaedter A., Schmelas C., Gunkel M., Dao Thi V.L., Grimm D. An RNA Interference/Adeno-Associated Virus Vector–Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus. Hepatol. Commun. 2022;6:878. doi: 10.1002/hep4.1842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1842</ArticleId><ArticleId IdType="pmc">PMC8948557</ArticleId><ArticleId IdType="pubmed">34719133</ArticleId></ArticleIdList></Reference><Reference><Citation>Boden D., Pusch O., Lee F., Tucker L., Ramratnam B. Human Immunodeficiency Virus Type 1 Escape from RNA Interference. J. Virol. 2003;77:11531–11535. doi: 10.1128/JVI.77.21.11531-11535.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.21.11531-11535.2003</ArticleId><ArticleId IdType="pmc">PMC229317</ArticleId><ArticleId IdType="pubmed">14557638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.A., Richardson C.D. Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region. J. Virol. 2005;79:7050–7058. doi: 10.1128/JVI.79.11.7050-7058.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.11.7050-7058.2005</ArticleId><ArticleId IdType="pmc">PMC1112103</ArticleId><ArticleId IdType="pubmed">15890944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. The RNA Helicase RIG-I Has an Essential Function in Double-Stranded RNA-Induced Innate Antiviral Responses. Nat. Immunol. 2004;5:730–737. doi: 10.1038/ni1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1087</ArticleId><ArticleId IdType="pubmed">15208624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V., Ellegast J., Kim S., Brzózka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., et al. 5′ Triphosphate RNA Is the Ligand for RIG-I. Science. 2006;314:994–997. doi: 10.1126/science.1132505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132505</ArticleId><ArticleId IdType="pubmed">17038590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichlmair A., Schulz O., Tan C.P., Näslund T.I., Liljeström P., Weber F., Reis E Sousa C. RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5′-Phosphates. Science. 2006;314:997–1001. doi: 10.1126/science.1132998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132998</ArticleId><ArticleId IdType="pubmed">17038589</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan Y., Yu Y., Ma Z., Khattar S.K., Fredericksen B., Zhang Y.-J. Hepatitis E Virus Inhibits Type I Interferon Induction by ORF1 Products. J. Virol. 2014;88:11924–11932. doi: 10.1128/JVI.01935-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01935-14</ArticleId><ArticleId IdType="pmc">PMC4178743</ArticleId><ArticleId IdType="pubmed">25100852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagdassarian E., Doceul V., Pellerin M., Demange A., Meyer L., Jouvenet N., Pavio N. The Amino-Terminal Region of Hepatitis E Virus ORF1 Containing a Methyltransferase (Met) and a Papain-Like Cysteine Protease (PCP) Domain Counteracts Type I Interferon Response. Viruses. 2018;10:726. doi: 10.3390/v10120726.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10120726</ArticleId><ArticleId IdType="pmc">PMC6315852</ArticleId><ArticleId IdType="pubmed">30567349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Yang Y., Nan Y., Ma Z., Yang L., Zhang Y.-J. The Capsid Protein of Hepatitis E Virus Inhibits Interferon Induction via Its N-Terminal Arginine-Rich Motif. Viruses. 2019;11:1050. doi: 10.3390/v11111050.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11111050</ArticleId><ArticleId IdType="pmc">PMC6928999</ArticleId><ArticleId IdType="pubmed">31717991</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Wang W., Li Y., Zhou X., Yin Y., Wang Y., de Man R.A., van der Laan L.J.W., Huang F., Kamar N., et al. RIG-I Is a Key Antiviral Interferon-Stimulated Gene against Hepatitis E Virus Regardless of Interferon Production. Hepatology. 2017;65:1823–1839. doi: 10.1002/hep.29105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29105</ArticleId><ArticleId IdType="pubmed">28195391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Liu Q., Berube N., Detmer S., Zhou Y. 5’-Triphosphate-Short Interfering RNA: Potent Inhibition of Influenza A Virus Infection by Gene Silencing and RIG-I Activation. J. Virol. 2012;86:10359–10369. doi: 10.1128/JVI.00665-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00665-12</ArticleId><ArticleId IdType="pmc">PMC3457308</ArticleId><ArticleId IdType="pubmed">22787226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Qian Y., Yan F., Tu J., Yang X., Xing Y., Chen Z. 5’-Triphosphate-siRNA Activates RIG-I-Dependent Type I Interferon Production and Enhances Inhibition of Hepatitis B Virus Replication in HepG2.2.15 Cells. Eur. J. Pharmacol. 2013;721:86–95. doi: 10.1016/j.ejphar.2013.09.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2013.09.050</ArticleId><ArticleId IdType="pubmed">24099962</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zhang C., Zhang J., Tian Z. Reversal of Hepatitis B Virus-Induced Immune Tolerance by an Immunostimulatory 3p-HBx-siRNAs in a Retinoic Acid Inducible Gene I-Dependent Manner. Hepatology. 2011;54:1179–1189. doi: 10.1002/hep.24505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24505</ArticleId><ArticleId IdType="pubmed">21721030</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D.B., Simmonds P., Izopet J., Oliveira-Filho E.F., Ulrich R.G., Johne R., Koenig M., Jameel S., Harrison T.J., Meng X.J., et al. Proposed Reference Sequences for Hepatitis E Virus Subtypes. J. Gen. Virol. 2016;97:537–542. doi: 10.1099/jgv.0.000393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000393</ArticleId><ArticleId IdType="pmc">PMC5588893</ArticleId><ArticleId IdType="pubmed">26743685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z.J., Mathews D.H. OligoWalk: An Online siRNA Design Tool Utilizing Hybridization Thermodynamics. Nucleic Acids Res. 2008;36:W104–W108. doi: 10.1093/nar/gkn250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn250</ArticleId><ArticleId IdType="pmc">PMC2447759</ArticleId><ArticleId IdType="pubmed">18490376</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito Y., Yoshimura J., Morishita S., Ui-Tei K. siDirect 2.0: Updated Software for Designing Functional siRNA with Reduced Seed-Dependent off-Target Effect. BMC Bioinform. 2009;10:392. doi: 10.1186/1471-2105-10-392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-10-392</ArticleId><ArticleId IdType="pmc">PMC2791777</ArticleId><ArticleId IdType="pubmed">19948054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurreck J. siRNA Efficiency: Structure or Sequence-That Is the Question. J. Biomed. Biotechnol. 2006;2006:83757. doi: 10.1155/JBB/2006/83757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/JBB/2006/83757</ArticleId><ArticleId IdType="pmc">PMC1559936</ArticleId><ArticleId IdType="pubmed">17057371</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckstein A., Grössl T., Geisler A., Wang X., Pinkert S., Pozzuto T., Schwer C., Kurreck J., Weger S., Vetter R., et al. Inhibition of Adenovirus Infections by siRNA-Mediated Silencing of Early and Late Adenoviral Gene Functions. Antivir. Res. 2010;88:86–94. doi: 10.1016/j.antiviral.2010.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.08.002</ArticleId><ArticleId IdType="pubmed">20708037</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmerer M., Apelt S., Trojnar E., Ulrich R.G., Wenzel J.J., Johne R. Enhanced Replication of Hepatitis E Virus Strain 47832c in an A549-Derived Subclonal Cell Line. Viruses. 2016;8:267. doi: 10.3390/v8100267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8100267</ArticleId><ArticleId IdType="pmc">PMC5086603</ArticleId><ArticleId IdType="pubmed">27690085</ArticleId></ArticleIdList></Reference><Reference><Citation>Johne R., Reetz J., Ulrich R.G., Machnowska P., Sachsenröder J., Nickel P., Hofmann J. An ORF1-Rearranged Hepatitis E Virus Derived from a Chronically Infected Patient Efficiently Replicates in Cell Culture. J. Viral Hepat. 2014;21:447–456. doi: 10.1111/jvh.12157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.12157</ArticleId><ArticleId IdType="pubmed">24750215</ArticleId></ArticleIdList></Reference><Reference><Citation>Todt D., Friesland M., Moeller N., Praditya D., Kinast V., Brüggemann Y., Knegendorf L., Burkard T., Steinmann J., Burm R., et al. Robust Hepatitis E Virus Infection and Transcriptional Response in Human Hepatocytes. Proc. Natl. Acad. Sci. USA. 2020;117:1731–1741. doi: 10.1073/pnas.1912307117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1912307117</ArticleId><ArticleId IdType="pmc">PMC6983376</ArticleId><ArticleId IdType="pubmed">31896581</ArticleId></ArticleIdList></Reference><Reference><Citation>Johne R., Trojnar E., Filter M., Hofmann J. Thermal Stability of Hepatitis E Virus as Estimated by a Cell Culture Method. Appl. Environ. Microbiol. 2016;82:4225–4231. doi: 10.1128/AEM.00951-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00951-16</ArticleId><ArticleId IdType="pmc">PMC4959202</ArticleId><ArticleId IdType="pubmed">27208095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jothikumar N., Cromeans T.L., Robertson B.H., Meng X.J., Hill V.R. A Broadly Reactive One-Step Real-Time RT-PCR Assay for Rapid and Sensitive Detection of Hepatitis E Virus. J. Virol. Methods. 2006;131:65–71. doi: 10.1016/j.jviromet.2005.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2005.07.004</ArticleId><ArticleId IdType="pubmed">16125257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Harms D., Papp C.P., Niendorf S., Jacobsen S., Lütgehetmann M., Pischke S., Wedermeyer H., Hofmann J., Bock C.-T. Comprehensive Molecular Approach for Characterization of Hepatitis E Virus Genotype 3 Variants. J. Clin. Microbiol. 2018;56:e01686-17. doi: 10.1128/JCM.01686-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01686-17</ArticleId><ArticleId IdType="pmc">PMC5925713</ArticleId><ArticleId IdType="pubmed">29514938</ArticleId></ArticleIdList></Reference><Reference><Citation>Matranga C., Tomari Y., Shin C., Bartel D.P., Zamore P.D. Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes. Cell. 2005;123:607–620. doi: 10.1016/j.cell.2005.08.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.08.044</ArticleId><ArticleId IdType="pubmed">16271386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Guo M., Wang X., Li J., Wang Y., Ye L., Dai M., Zhou L., Persidsky Y., Ho W. TLR3 Activation Efficiency by High or Low Molecular Mass Poly I:C. Innate Immun. 2013;19:184–192. doi: 10.1177/1753425912459975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425912459975</ArticleId><ArticleId IdType="pmc">PMC3942089</ArticleId><ArticleId IdType="pubmed">23035017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Cheng G., Mahato R.I. RNAi for Treating Hepatitis B Viral Infection. Pharm. Res. 2008;25:72–86. doi: 10.1007/s11095-007-9504-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-007-9504-0</ArticleId><ArticleId IdType="pmc">PMC2217617</ArticleId><ArticleId IdType="pubmed">18074201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia S.B., Brideau-Andersen A., Chisari F.V. Interference of Hepatitis C Virus RNA Replication by Short Interfering RNAs. Proc. Natl. Acad. Sci. USA. 2003;100:2014–2018. doi: 10.1073/pnas.252783999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.252783999</ArticleId><ArticleId IdType="pmc">PMC149950</ArticleId><ArticleId IdType="pubmed">12566571</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein E.A., Pinkert S., Becher P.M., Geisler A., Zeichhardt H., Klopfleisch R., Poller W., Tschöpe C., Lassner D., Fechner H., et al. Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-Induced Myocarditis in Mice. J. Infect. Dis. 2015;211:613–622. doi: 10.1093/infdis/jiu504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu504</ArticleId><ArticleId IdType="pubmed">25193982</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H., Saitoh H., Suzuki T., Takaku H. Baculovirus-Mediated Bispecific Short-Hairpin Small-Interfering RNAs Have Remarkable Ability to Cope With Both Influenza Viruses A and B. Oligonucleotides. 2009;19:307–316. doi: 10.1089/oli.2009.0189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/oli.2009.0189</ArticleId><ArticleId IdType="pubmed">19899951</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A., Dieringer B., Elsner L., Klingel K., Klopfleisch R., Vornlocher H.-P., Kurreck J., Fechner H. Lipid Nanoparticle-Encapsulated, Chemically Modified Anti-Adenoviral siRNAs Inhibit Hepatic Adenovirus Infection in Immunosuppressed Syrian Hamsters. Mol. Ther. Nucleic Acids. 2023;32:923–936. doi: 10.1016/j.omtn.2023.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2023.05.016</ArticleId><ArticleId IdType="pmc">PMC10280093</ArticleId><ArticleId IdType="pubmed">37346978</ArticleId></ArticleIdList></Reference><Reference><Citation>Saayman S., Barichievy S., Capovilla A., Morris K.V., Arbuthnot P., Weinberg M.S. The Efficacy of Generating Three Independent Anti-HIV-1 siRNAs from a Single U6 RNA Pol III-Expressed Long Hairpin RNA. PLoS ONE. 2008;3:2602. doi: 10.1371/journal.pone.0002602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002602</ArticleId><ArticleId IdType="pmc">PMC2434202</ArticleId><ArticleId IdType="pubmed">18596982</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhout B., ter Brake O. Towards a Durable RNAi Gene Therapy for HIV-AIDS. Expert Opin. Biol. Ther. 2009;9:161–170. doi: 10.1517/14712590802653619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712590802653619</ArticleId><ArticleId IdType="pubmed">19236246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.P., von Eije K.J., Schopman N.C.T., Westerink J.-T., ter Brake O., Haasnoot J., Berkhout B. Combinatorial RNAi against HIV-1 Using Extended Short Hairpin RNAs. Mol. Ther. J. Am. Soc. Gene Ther. 2009;17:1712–1723. doi: 10.1038/mt.2009.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.176</ArticleId><ArticleId IdType="pmc">PMC2835024</ArticleId><ArticleId IdType="pubmed">19672247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolksdorf B., Nie C., Niemeyer D., Röhrs V., Berg J., Lauster D., Adler J.M., Haag R., Trimpert J., Kaufer B., et al. Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence. Viruses. 2021;13:2030. doi: 10.3390/v13102030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13102030</ArticleId><ArticleId IdType="pmc">PMC8539227</ArticleId><ArticleId IdType="pubmed">34696460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolksdorf B., Heinze J., Niemeyer D., Röhrs V., Berg J., Drosten C., Kurreck J. Development of a Highly Stable, Active Small Interfering RNA with Broad Activity against SARS-CoV Viruses. Antivir. Res. 2024;226:105879. doi: 10.1016/j.antiviral.2024.105879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2024.105879</ArticleId><ArticleId IdType="pubmed">38599550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju X., Xiang G., Gong M., Yang R., Qin J., Li Y., Nan Y., Yang Y., Zhang Q.C., Ding Q. Identification of Functional Cis-Acting RNA Elements in the Hepatitis E Virus Genome Required for Viral Replication. PLoS Pathog. 2020;16:e1008488. doi: 10.1371/journal.ppat.1008488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008488</ArticleId><ArticleId IdType="pmc">PMC7239442</ArticleId><ArticleId IdType="pubmed">32433693</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tong H., Hoan N.X., Wang B., Wedemeyer H., Bock C.-T., Velavan T.P. Hepatitis E Virus Mutations: Functional and Clinical Relevance. EBioMedicine. 2016;11:31–42. doi: 10.1016/j.ebiom.2016.07.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2016.07.039</ArticleId><ArticleId IdType="pmc">PMC5049923</ArticleId><ArticleId IdType="pubmed">27528267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett D.W., Davis M.E. Insights into the Kinetics of siRNA-Mediated Gene Silencing from Live-Cell and Live-Animal Bioluminescent Imaging. Nucleic Acids Res. 2006;34:322–333. doi: 10.1093/nar/gkj439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkj439</ArticleId><ArticleId IdType="pmc">PMC1331994</ArticleId><ArticleId IdType="pubmed">16410612</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M., Nagai C., Hatakeyama H., Minakawa N., Harashima H., Matsuda A. Intracellular Stability of 2′-OMe-4′-Thioribonucleoside Modified siRNA Leads to Long-Term RNAi Effect. Nucleic Acids Res. 2012;40:5787–5793. doi: 10.1093/nar/gks204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks204</ArticleId><ArticleId IdType="pmc">PMC3384325</ArticleId><ArticleId IdType="pubmed">22411910</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M., Hofmann J., Köhler A., Wang B., Bock C.-T., Schott E., Reinke P., Nickel P. Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes. Transplant. Direct. 2018;4:e341. doi: 10.1097/TXD.0000000000000758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TXD.0000000000000758</ArticleId><ArticleId IdType="pmc">PMC5811270</ArticleId><ArticleId IdType="pubmed">29464202</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms D., Choi M., Allers K., Wang B., Pietsch H., Papp C.-P., Hanisch L., Kurreck J., Hofmann J., Bock C.-T. Specific Circulating microRNAs during Hepatitis E Infection Can Serve as Indicator for Chronic Hepatitis E. Sci. Rep. 2020;10:5337. doi: 10.1038/s41598-020-62159-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62159-9</ArticleId><ArticleId IdType="pmc">PMC7093451</ArticleId><ArticleId IdType="pubmed">32210284</ArticleId></ArticleIdList></Reference><Reference><Citation>Rau F., Elsner C., Meister T.L., Gömer A., Kallies R., Dittmer U., Steinmann E., Todt D. Monitoring of Hepatitis E Virus in Wastewater Can Identify Clinically Relevant Variants. Liver Int. 2024;44:637–643. doi: 10.1111/liv.15842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.15842</ArticleId><ArticleId IdType="pubmed">38291853</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmerer M., Wenzel J.J., Stark K., Faber M. Molecular Epidemiology and Genotype-Specific Disease Severity of Hepatitis E Virus Infections in Germany, 2010–2019. Emerg. Microbes Infect. 2022;11:1754–1763. doi: 10.1080/22221751.2022.2091479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2091479</ArticleId><ArticleId IdType="pmc">PMC9295818</ArticleId><ArticleId IdType="pubmed">35713010</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldipur B., Bhukya P.L., Arankalle V., Lole K. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122. J. Virol. 2018;92:e01999-17. doi: 10.1128/JVI.01999-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01999-17</ArticleId><ArticleId IdType="pmc">PMC5952168</ArticleId><ArticleId IdType="pubmed">29540601</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller C., Obermann W., Schulte F.W., Lange-Grünweller K., Oestereich L., Elgner F., Glitscher M., Hildt E., Singh K., Wendel H.-G., et al. Comparison of Broad-Spectrum Antiviral Activities of the Synthetic Rocaglate CR-31-B (−) and the eIF4A-Inhibitor Silvestrol. Antivir. Res. 2020;175:104706. doi: 10.1016/j.antiviral.2020.104706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104706</ArticleId><ArticleId IdType="pmc">PMC7114339</ArticleId><ArticleId IdType="pubmed">31931103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasheri N., Doctor T., Chen A., Harlow J., Gill A. Evaluation of High-Pressure Processing in Inactivation of the Hepatitis E Virus. Front. Microbiol. 2020;11:461. doi: 10.3389/fmicb.2020.00461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.00461</ArticleId><ArticleId IdType="pmc">PMC7105680</ArticleId><ArticleId IdType="pubmed">32265886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G., Monini M., Ammendolia M.G., De Sabato L., Ostanello F., Vaccari G., Di Bartolo I. In Vitro Replication of Swine Hepatitis E Virus (HEV): Production of Cell-Adapted Strains. Animals. 2023;13:276. doi: 10.3390/ani13020276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ani13020276</ArticleId><ArticleId IdType="pmc">PMC9854997</ArticleId><ArticleId IdType="pubmed">36670816</ArticleId></ArticleIdList></Reference><Reference><Citation>Primadharsini P.P., Takahashi M., Nishizawa T., Sato Y., Nagashima S., Murata K., Okamoto H. The Full-Genome Analysis and Generation of an Infectious cDNA Clone of a Genotype 6 Hepatitis E Virus Variant Obtained from a Japanese Wild Boar: In Vitro Cultivation in Human Cell Lines. Viruses. 2024;16:842. doi: 10.3390/v16060842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16060842</ArticleId><ArticleId IdType="pmc">PMC11209168</ArticleId><ArticleId IdType="pubmed">38932135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R.M., Decker C.C., Dao Thi V.L. Cell Culture Models for Hepatitis E Virus. Viruses. 2019;11:608. doi: 10.3390/v11070608.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11070608</ArticleId><ArticleId IdType="pmc">PMC6669563</ArticleId><ArticleId IdType="pubmed">31277308</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister T.L., Bruening J., Todt D., Steinmann E. Cell Culture Systems for the Study of Hepatitis E Virus. Antivir. Res. 2019;163:34–49. doi: 10.1016/j.antiviral.2019.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.01.007</ArticleId><ArticleId IdType="pubmed">30653997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin M., Hirchaud E., Blanchard Y., Pavio N., Doceul V. Characterization of a Cell Culture System of Persistent Hepatitis E Virus Infection in the Human HepaRG Hepatic Cell Line. Viruses. 2021;13:406. doi: 10.3390/v13030406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030406</ArticleId><ArticleId IdType="pmc">PMC8001476</ArticleId><ArticleId IdType="pubmed">33806591</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt K., Berg J., Roehrs V., Kurreck J., Al-Zeer M.A. 3D-Bioprinted HepaRG Cultures as a Model for Testing Long Term Aflatoxin B1 Toxicity in Vitro. Toxicol. Rep. 2020;7:1578–1587. doi: 10.1016/j.toxrep.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxrep.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7708771</ArticleId><ArticleId IdType="pubmed">33304827</ArticleId></ArticleIdList></Reference><Reference><Citation>Merl S., Michaelis C., Jaschke B., Vorpahl M., Seidl S., Wessely R. Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice. Circulation. 2005;111:1583–1592. doi: 10.1161/01.CIR.0000160360.02040.AB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000160360.02040.AB</ArticleId><ArticleId IdType="pubmed">15795330</ArticleId></ArticleIdList></Reference><Reference><Citation>Werk D., Schubert S., Lindig V., Grunert H.-P., Zeichhardt H., Erdmann V.A., Kurreck J. Developing an Effective RNA Interference Strategy against a Plus-Strand RNA Virus: Silencing of Coxsackievirus B3 and Its Cognate Coxsackievirus-Adenovirus Receptor. Biol. Chem. 2005;386:857–863. doi: 10.1515/BC.2005.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/BC.2005.100</ArticleId><ArticleId IdType="pubmed">16164410</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Khvorova A. RNAi-Based Drug Design: Considerations and Future Directions. Nat. Rev. Drug Discov. 2024;23:341–364. doi: 10.1038/s41573-024-00912-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-024-00912-9</ArticleId><ArticleId IdType="pmc">PMC11144061</ArticleId><ArticleId IdType="pubmed">38570694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller L., Lin C., Price A., Kottilil S., Chua J.V. RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects. Microorganisms. 2024;12:599. doi: 10.3390/microorganisms12030599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms12030599</ArticleId><ArticleId IdType="pmc">PMC10974478</ArticleId><ArticleId IdType="pubmed">38543650</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangamani L., Balasubramanian B., Easwaran M., Natarajan J., Pushparaj K., Meyyazhagan A., Piramanayagam S. GalNAc-siRNA Conjugates: Prospective Tools on the Frontier of Anti-Viral Therapeutics. Pharmacol. Res. 2021;173:105864. doi: 10.1016/j.phrs.2021.105864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105864</ArticleId><ArticleId IdType="pmc">PMC8405237</ArticleId><ArticleId IdType="pubmed">34474100</ArticleId></ArticleIdList></Reference><Reference><Citation>Merl S., Wessely R. Anti-Coxsackieviral Efficacy of RNA Interference Is Highly Dependent on Genomic Target Selection and Emergence of Escape Mutants. Oligonucleotides. 2007;17:44–53. doi: 10.1089/oli.2007.0057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/oli.2007.0057</ArticleId><ArticleId IdType="pubmed">17461762</ArticleId></ArticleIdList></Reference><Reference><Citation>ter Brake O., Konstantinova P., Ceylan M., Berkhout B. Silencing of HIV-1 with RNA Interference: A Multiple shRNA Approach. Mol. Ther. J. Am. Soc. Gene Ther. 2006;14:883–892. doi: 10.1016/j.ymthe.2006.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2006.07.007</ArticleId><ArticleId IdType="pubmed">16959541</ArticleId></ArticleIdList></Reference><Reference><Citation>Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S.S., Kirschnek S., Gaffal E., Landsberg J., Hellmuth J., et al. 5′-Triphosphate-siRNA: Turning Gene Silencing and Rig-I Activation against Melanoma. Nat. Med. 2008;14:1256–1263. doi: 10.1038/nm.1887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1887</ArticleId><ArticleId IdType="pubmed">18978796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauletbaev N., Cammisano M., Herscovitch K., Lands L.C. Stimulation of the RIG-I/MAVS Pathway by Polyinosinic:Polycytidylic Acid Upregulates IFN-β in Airway Epithelial Cells with Minimal Costimulation of IL-8. J. Immunol. 2015;195:2829–2841. doi: 10.4049/jimmunol.1400840.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1400840</ArticleId><ArticleId IdType="pubmed">26283481</ArticleId></ArticleIdList></Reference><Reference><Citation>Devhare P.B., Desai S., Lole K.S. Innate Immune Responses in Human Hepatocyte-Derived Cell Lines Alter Genotype 1 Hepatitis E Virus Replication Efficiencies. Sci. Rep. 2016;6:26827. doi: 10.1038/srep26827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26827</ArticleId><ArticleId IdType="pmc">PMC4882509</ArticleId><ArticleId IdType="pubmed">27230536</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>